User login
BERLIN—Data from the GARFIELD-VTE registry showed that, in the first 6 months after a patient was diagnosed with venous thromboembolism (VTE), death was the most frequent major adverse outcome.
More than half of the deaths were related to cancer, with small percentages of patients dying from VTE complications and bleeding events.
GARFIELD-VTE is a prospective registry designed to provide insight into the management of VTE in everyday clinical practice.
Six-month results from the registry were presented in a poster at the International Society on Thrombosis and Haemostasis (ISTH) 2017 Congress (PB 1196).
The GARFIELD-VTE registry has enrolled more than 10,000 patients with acute VTE—including deep vein thrombosis (DVT) and pulmonary embolism (PE)—from across 415 sites in 28 countries.
Alexander G. G. Turpie, MD, of McMaster University in Hamilton, Ontario, Canada, and his colleagues presented data on 10,315 patients with at least 6 months of follow-up.
Baseline characteristics
The patients’ median age was 60.2 (range, 46.2-71.7), and 49.9% were female. Most patients were white (69.3%), 19.6% were Asian, 4.4% were black, 0.6% were multiracial, 4.3% were classified as “other,” and 1.9% were of unknown race.
Six percent of patients had a family history of VTE (first-degree relatives), 15.1% had a prior episode of DVT and/or PE themselves, and 37.5% had at least 1 provoking factor for VTE.
Most patients (61.8%) had DVT alone, but 38.3% had PE with or without DVT.
The registry included patients with active cancer (9.1%), a history of cancer (10.7%), thrombophilia (2.9%), chronic immobilization (5.6%), heart failure (3.2%), and renal insufficiency (3.5%).
Outcomes
Over 6 months of follow-up, the following events were reported:
- Any bleeding—622 total bleeds or 13.6 per 100 person-years
- All-cause mortality—460 total deaths or 9.7 per 100 person-years
- Recurrent VTE—169 events or 3.6 per 100 person-years
- Major bleeding—106 events or 2.2 per 100 person-years
- Myocardial infarction—42 events or 0.9 per 100 person-years
- Stroke/transient ischemic attack—38 events or 0.8 per 100 person-years.
Nearly 5% of patients died (4.5%, n=460). More than half (54.3%, n=250) of these deaths were cancer-related.
Other causes of death included:
- Cardiac death—7.0% (n=32)
- PE—3.5% (n=16)
- Bleeding—3.3% (n=15)
- VTE complications—1.3% (n=6)
- Stroke—1.1% (n=5)
- Other cause—17.8% (n=82)
- Unknown cause—11.7% (n=54).
Additional data from the GARFIELD-VTE registry were presented at ISTH 2017 as posters (PB 460 and PB 1188) and in an oral presentation (ASY 35.4). The next set of data from the registry is slated to be presented at the 2017 ASH Annual Meeting.
GARFIELD-VTE is supported by an unrestricted educational grant from Bayer AG. For further information on the registry, visit http://www.garfieldregistry.org. 
BERLIN—Data from the GARFIELD-VTE registry showed that, in the first 6 months after a patient was diagnosed with venous thromboembolism (VTE), death was the most frequent major adverse outcome.
More than half of the deaths were related to cancer, with small percentages of patients dying from VTE complications and bleeding events.
GARFIELD-VTE is a prospective registry designed to provide insight into the management of VTE in everyday clinical practice.
Six-month results from the registry were presented in a poster at the International Society on Thrombosis and Haemostasis (ISTH) 2017 Congress (PB 1196).
The GARFIELD-VTE registry has enrolled more than 10,000 patients with acute VTE—including deep vein thrombosis (DVT) and pulmonary embolism (PE)—from across 415 sites in 28 countries.
Alexander G. G. Turpie, MD, of McMaster University in Hamilton, Ontario, Canada, and his colleagues presented data on 10,315 patients with at least 6 months of follow-up.
Baseline characteristics
The patients’ median age was 60.2 (range, 46.2-71.7), and 49.9% were female. Most patients were white (69.3%), 19.6% were Asian, 4.4% were black, 0.6% were multiracial, 4.3% were classified as “other,” and 1.9% were of unknown race.
Six percent of patients had a family history of VTE (first-degree relatives), 15.1% had a prior episode of DVT and/or PE themselves, and 37.5% had at least 1 provoking factor for VTE.
Most patients (61.8%) had DVT alone, but 38.3% had PE with or without DVT.
The registry included patients with active cancer (9.1%), a history of cancer (10.7%), thrombophilia (2.9%), chronic immobilization (5.6%), heart failure (3.2%), and renal insufficiency (3.5%).
Outcomes
Over 6 months of follow-up, the following events were reported:
- Any bleeding—622 total bleeds or 13.6 per 100 person-years
- All-cause mortality—460 total deaths or 9.7 per 100 person-years
- Recurrent VTE—169 events or 3.6 per 100 person-years
- Major bleeding—106 events or 2.2 per 100 person-years
- Myocardial infarction—42 events or 0.9 per 100 person-years
- Stroke/transient ischemic attack—38 events or 0.8 per 100 person-years.
Nearly 5% of patients died (4.5%, n=460). More than half (54.3%, n=250) of these deaths were cancer-related.
Other causes of death included:
- Cardiac death—7.0% (n=32)
- PE—3.5% (n=16)
- Bleeding—3.3% (n=15)
- VTE complications—1.3% (n=6)
- Stroke—1.1% (n=5)
- Other cause—17.8% (n=82)
- Unknown cause—11.7% (n=54).
Additional data from the GARFIELD-VTE registry were presented at ISTH 2017 as posters (PB 460 and PB 1188) and in an oral presentation (ASY 35.4). The next set of data from the registry is slated to be presented at the 2017 ASH Annual Meeting.
GARFIELD-VTE is supported by an unrestricted educational grant from Bayer AG. For further information on the registry, visit http://www.garfieldregistry.org.
BERLIN—Data from the GARFIELD-VTE registry showed that, in the first 6 months after a patient was diagnosed with venous thromboembolism (VTE), death was the most frequent major adverse outcome.
More than half of the deaths were related to cancer, with small percentages of patients dying from VTE complications and bleeding events.
GARFIELD-VTE is a prospective registry designed to provide insight into the management of VTE in everyday clinical practice.
Six-month results from the registry were presented in a poster at the International Society on Thrombosis and Haemostasis (ISTH) 2017 Congress (PB 1196).
The GARFIELD-VTE registry has enrolled more than 10,000 patients with acute VTE—including deep vein thrombosis (DVT) and pulmonary embolism (PE)—from across 415 sites in 28 countries.
Alexander G. G. Turpie, MD, of McMaster University in Hamilton, Ontario, Canada, and his colleagues presented data on 10,315 patients with at least 6 months of follow-up.
Baseline characteristics
The patients’ median age was 60.2 (range, 46.2-71.7), and 49.9% were female. Most patients were white (69.3%), 19.6% were Asian, 4.4% were black, 0.6% were multiracial, 4.3% were classified as “other,” and 1.9% were of unknown race.
Six percent of patients had a family history of VTE (first-degree relatives), 15.1% had a prior episode of DVT and/or PE themselves, and 37.5% had at least 1 provoking factor for VTE.
Most patients (61.8%) had DVT alone, but 38.3% had PE with or without DVT.
The registry included patients with active cancer (9.1%), a history of cancer (10.7%), thrombophilia (2.9%), chronic immobilization (5.6%), heart failure (3.2%), and renal insufficiency (3.5%).
Outcomes
Over 6 months of follow-up, the following events were reported:
- Any bleeding—622 total bleeds or 13.6 per 100 person-years
- All-cause mortality—460 total deaths or 9.7 per 100 person-years
- Recurrent VTE—169 events or 3.6 per 100 person-years
- Major bleeding—106 events or 2.2 per 100 person-years
- Myocardial infarction—42 events or 0.9 per 100 person-years
- Stroke/transient ischemic attack—38 events or 0.8 per 100 person-years.
Nearly 5% of patients died (4.5%, n=460). More than half (54.3%, n=250) of these deaths were cancer-related.
Other causes of death included:
- Cardiac death—7.0% (n=32)
- PE—3.5% (n=16)
- Bleeding—3.3% (n=15)
- VTE complications—1.3% (n=6)
- Stroke—1.1% (n=5)
- Other cause—17.8% (n=82)
- Unknown cause—11.7% (n=54).
Additional data from the GARFIELD-VTE registry were presented at ISTH 2017 as posters (PB 460 and PB 1188) and in an oral presentation (ASY 35.4). The next set of data from the registry is slated to be presented at the 2017 ASH Annual Meeting.
GARFIELD-VTE is supported by an unrestricted educational grant from Bayer AG. For further information on the registry, visit http://www.garfieldregistry.org.